Functional genomics in primary T cells and monocytes identifies mechanisms by which genetic susceptibility loci influence systemic sclerosis risk

David González-Serna[1,$,*], Chenfu Shi[2,$], Martin Kerick[1], Jenny Hankinson[3], James Ding[2], Amanda McGovern[2], Mauro Tutino[3], Gonzalo Villanueva Martin[4], Norberto Ortego-Centeno[4], José Luis Callejas[4], Javier Martin[1,§] & Gisela Orozco[2,5,§,*]

[1]Institute of Parasitology and Biomedicine López-Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Granada, Spain.
[2]Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
[3]Division of Infection, Immunity & Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
[4]Department of Internal medicine, Hospital Universitario San Cecilio, Institute for Biosanitary Research of Granada (ibs.GRANADA), Granada, Spain.
[5]NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
[$]Joint first authors.
[§]Joint senior authors.

*Correspondence to David González-Serna (email: sna.david@ipb.csic.es) and Gisela Orozco (Gisela.Orozco@manchester.ac.uk)

Funding: This work was supported by the Spanish Ministry of Science and Innovation (grants RTI2018101332-B-100 and SAF2015-66761-P), the Cooperative Research Thematic Network (RETICS) programme (RD16/0012/0013) (RIER) from Instituto de Salud Carlos III (ISCIII, Spanish Ministry of Economy, Industry and Competitiveness), the Wellcome Trust (award references 207491/Z/17/Z and 215207/Z/19/Z), Versus Arthritis (award reference 21754), and the NIHR Manchester Biomedical Research Centre.

ABSTRACT

Objectives. Systemic sclerosis (SSc) is a complex autoimmune disease with a strong genetic component. However, most of the genes associated to the disease are still unknown because associated variants affect mostly non-coding intergenic elements of the genome. The challenge now is to use functional genomics to translate the genetic findings into a better understanding of the disease.

Methods. Promoter capture Hi-C and RNA sequencing experiments were performed in $CD4^+$ T cells and $CD14^+$ monocytes samples from 10 SSc patients and 5 healthy controls to link SSc-associated variants with their target genes, followed by differential expression and differential interaction analyses between cell types.

Results. We linked SSc-associated loci to 39 new potential target genes and confirm 7 previously known genes. We highlight novel causal genes, such as *CXCR5* as the most probable candidate gene for the *DDX6* locus. Some previously known SSc associated genes such as *IRF8, STAT4*, or *CD247* interestingly showed cell type specific interactions. We also identified 15 potential drug targets already in use in other similar immune-mediated diseases that could be repurposed for SSc treatment. Furthermore, we observed that interactions are directly correlated with the expression of important genes implicated in cell type specific pathways and find evidence that chromatin conformation is associated with genotype.

Conclusions. Our study reveals potential causal genes for SSc-associated loci, some of them acting in a cell type specific manner, suggesting novel biological mechanisms that might mediate SSc pathogenesis.

INTRODUCTION

Systemic sclerosis (SSc) is a complex chronic immune-mediated disease that affects the connective tissue, characterized by an immune imbalance, vascular alterations, and an excessive collagen deposition leading to fibrosis (1). Several lines of evidence implicate T cells and monocytes/macrophages as important cell types in SSc pathogenesis (2,3). In this regard, modifications in the proportions of CD4[+] T cell subpopulations, and their functional alterations may contribute to the vascular dysregulation and fibrosis observed in the disease (4,5). On the other hand, circulating monocytes/macrophages with a profibrotic phenotype are increased in blood from SSc patients (6,7), and changes in human monocyte-derived macrophages transcriptome are related to SSc genetic variants (8).

SSc presents a complex genetic component, and its etiology is poorly understood. Large-scale genetic studies have so far identified 27 independent signals associated with susceptibility to SSc (9,10). Interestingly, many of the different genes assigned to SSc GWAS loci are related to T cell activation and macrophages regulation pathways (11,12), and are shared among immune-mediated diseases, which may be of interest in the drug repositioning of rare diseases like SSc, where there are no specific available treatments (13). However, the majority of single nucleotide polymorphisms (SNPs) associated with SSc map to non-coding regions of the genome that are enriched in enhancer elements, which are often cell-type specific (14,15). These regulatory elements can interact with genes often located hundreds of kilobases away, bypassing in many cases nearby genes (16).

Thus, the current challenge remains in linking disease-associated regions with the genes that they affect, in the specific cell types involved, in order to pinpoint to the mechanisms and the biological pathways implicated in genetically susceptible patients (17). In this regard, many techniques to analyze the three-dimensional genome architecture have emerged, such as chromosome conformation capture (3C) (18,19), that can help us annotate these genetic variants. The most powerful technique developed to date, Hi-C allows the identification of chromosomal interactions genome-wide (20). A more recent technique, capture Hi-C (CHi-C) allows to specifically enrich chromosomal regions of interest, such as disease risk loci (region CHi-C) or promoters (promoter CHi-C, pCHi-C) from Hi-C libraries in a cost-effective way (21). This technique has been successfully applied in different cell types to link enhancers and non-coding disease variants to potential target genes (22). Previously, we successfully applied CHi-C to identify disease causal genes and potential drugs for repositioning in autoimmune diseases using cell lines (23,24). Since the regulation of gene expression and chromatin conformation is highly context specific, it is essential to apply these technologies to primary cells isolated from patients. Moreover, recent evidence points to alterations in chromatin conformation linked to genotype, but these studies have so far only been carried out in a limited way and in cell lines (25,26).

In this study, we used pCHi-C in two of the most relevant cell types in SSc pathogenesis: CD4[+] T cells and CD14[+] monocytes from SSc patients and healthy controls in an attempt to

annotate gene targets within all known SSc GWAS loci. We also integrate this data with RNA-seq, eQTLs and genotype information to create a multi-omic approach in order to identify interactomic and transcriptomic differences between cell types and disease state that could be of interest in the pathogenesis of SSc.

MATERIAL AND METHODS

Please see **Supplementary Material and Methods** for more details.

Isolation of CD4+ T cells and CD14+ monocytes

Primary CD4+ T cells and CD14+ monocytes were collected from 10 systemic sclerosis patients and 5 healthy individuals. All SSc patients were diagnosed according to the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2013 criteria (cohorts characteristics described in **Supplementary Table 1**). All patients and

controls gave written informed consent, which was approved by the local ethics committees. Peripheral blood mononuclear cells (PBMCs) were isolated from 70 ml blood samples using Ficoll density gradient centrifugation. The EasySep Human CD14+ Positive selection kit (StemCell Technologies, ref:17858) was used to isolate CD14+ cells from PBMCs and, subsequently, the Easysep CD4+ T cell isolation kit (StemCell Technologies, ref:17952) was used to isolate CD4+ T cells from the remaining PBMCs, according to the manufacturer's instructions.

Capture Hi-C library generation and processing

5-10 million isolated CD4+ T cells and CD14+ monocytes were crosslinked in 1% formaldehyde; the reaction was then quenched with 0.125 M glycine. Each Hi-C library was prepared from fixed cells following the Arima HiC kit (Arima Genomics) and the KAPA HyperPrep kit (KAPA Biosystems) following the manufacturer's protocol. Hi-C samples were then hybridized with the SureSelect custom capture library by following Agilent SureSelectXT HS reagents (ref: G9702A, G9496A) and protocols (ref: G9702-9000).

Reads were mapped on the GRCh38 genome with HiCUP v0.7.4 (27) and bowtie2 v2.3.2 (Statistics in **Supplementary Table 2**). Significant chromatin interactions were identified using CHiCAGO v1.13.1 (28) using a threshold of CHiCAGO score > 5 in different conditions; cell type: CD4+ T cells (n=15) and CD14+ monocytes (n=15); cell type and disease state: CD4+ T cells from SSc patients (n=10) and healthy controls (n=5), and CD14+ monocytes from SSc patients (n=10) and healthy controls (n=5). Principal component analysis (PCA) was performed in each cell type in order to detect potential biases (**Supplementary Figure 1**).

Chicdiff v0.6 (29) was used to detect differential interactions between different conditions: CD4+ T cells vs CD14+ monocytes; SSc patients vs healthy controls CD4+ T cells; and SSc patients vs healthy controls CD14+ monocytes. For each comparison, only those interactions with CHiCAGO score > 5 in at least one condition were included in differential analysis. Differential interactions with a weighted adjusted p-value < 0.05 were identified as significant. Spearman's rank-order correlation was performed to test the correlation of $\log_2$ fold change values in differential interactions between patients and controls in CD4+ T cells and CD14+ monocytes.

Genotype calling and allele specific analysis

Genotypes were called using GLIMPSE v1.1.1 (30) from Capture Hi-C reads aligned using HICUP v0.7.4 (27) to a masked GRCh38 genome. Genotype phasing was then carried out using the integrated phasing pipeline (31) which integrates population phasing with reads phasing using the Capture Hi-C reads. Reads were then split using SNPsplit v0.5.0 (32) generating allele specific alignments. Counts were for each allele for each CHiCAGO significant loop were then calculated using bedtools v2.30 (33) and data was integrated in Python 3.9. Allelic imbalance of the reads was tested using a binomial test for each sample which has heterozygous for that SNP and satisfied some requirements (see supplementary methods). All the resulting p-values were then checked for directionality and merged using the Firsher's method for meta-analysis. Resulting p-values were then corrected using Benjamini-Hochberg method.

RNA-seq library generation and processing
RNA was isolated from 0.5 million purified cells using the RNeasy microkit (QIAGEN, ref: 74004). Libraries were generated using Illumina Truseq Stranded Total RNA reagents and protocol, except for Control 1 CD4$^+$ and CD14$^+$ samples, for which library preparation failed. Reads were mapped using STAR v2.7.3a on the GRCh38 genome with GENCODE annotation v32. Reads were de-duplicated and then counted (**Supplementary Table 3**). Final count matrices were analyzed using edgeR v3.28.1 to perform normalization and differential expression analysis. Differentially expressed genes were called with an adjusted p-value of 0.1 (FDR 10%). Functional enrichment analyses were performed with g:Profiler (34) with default settings.

Linking differential expression and differential interactions in CD4$^+$ T cells vs CD14$^+$ monocytes
Genes corresponding with the promoter end of significant differential interactions observed between CD4$^+$ and CD14$^+$ cells were overlapped with those differentially expressed. One-sided Fisher's exact test was performed in order to calculate the enrichment of genes with differential interactions in those differentially expressed. In this set of overlapping genes, Spearman's rank-order correlation was performed to test the correlation of $\log_2$ fold change values in differential interactions and differential expression. Finally, in order to test the distribution of $\log_2$ fold change values, a binomial exact test was performed on a subset of overlapping genes obtained adding a more stringent cutoff (absolute value of median $\log_2 FC$ > 2 for each gene). Functional enrichment analyses were performed with g:Profiler (34) with default settings.

Defining SSc GWAS loci
All independent non-MHC disease-associated signals for SSc were selected from the largest meta-GWAS performed to date (9). We defined 23 regions based on linkage disequilibrium data and SNP proximity from the total of 27 independent signals described in GWAS. The window ranges and total number of SNPs in each of the 23 final loci are specified in **Supplementary Table S4**.

Identifying eQTL genes for SSc GWAS loci

Publicly available eQTL databases were downloaded from the DICE eQTL database (35) of isolated immune cells and the eQTLgen (second release) database (36) of blood eQTLs. Genes were linked to each GWAS loci if the lead SNP was linked to a gene in the respective databases.

Defining enhancers and TADs in CD4+ T cells and CD14+ monocytes
In order to define enhancer regions, chromHMM v1.22 annotations from 9 CD4+ T cells and 4 CD14+ monocytes were downloaded from the epiMAP project (37). For each cell type, enhancer regions were defined as those with state number from chromHMM corresponding to enhancer activity present in at least one sample. TADs definitions for CD4+ T cells and CD14+ monocytes were obtained from Javierre et al. (22).

Overlap between pCHi-C, SSc GWAS loci, and enhancer regions
In order to prioritize certain interactions observed in pCHi-C data of particular interest in SSc GWAS loci, the SNP set previously defined in "Defining SSc GWAS loci" was overlapped with enhancer regions of each cell type (**Supplementary Table 4**). This new SNP set was then overlapped with the promoter interacting regions (PIRs) of significant pCHi-C interactions, defining candidate interacting genes as those in which their PIR overlaps with our significant SSc SNP set and enhancer regions. Garfield v2 (38) was used to estimate the enrichment of the GWAS SNPs in CD4+ T cells and CD14+ monocytes enhancer regions using a p-value threshold of $1x10^{-8}$. Functional enrichment analyses were performed for the sets of interacting genes observed in CD4+ T cells and CD14+ monocytes with g:Profiler (34).

Drug target analysis
In order to assess if genes interacting with SSc GWAS loci in CD4+ T cells and CD14+ monocytes presented potential drug targets that could be repurposed for its use in SSc, those genes interacting with PIR overlapping significant SSc GWAS SNPs and enhancer regions, were used to model a protein-protein interaction (PPI) network using STRING v11 (39) (**Supplementary Table 5**). Protein products from these genes and those in direct PPI with them were used to query the OpenTargets Platform for drug targets. Additionally, the same platform and the Drugbank database were searched for information on clinical studies of drug targets of interest in SSc.

RESULTS

In this study we generated pCHi-C data for CD4$^+$ T cells and CD14$^+$ monocytes from 10 SSc patients and 5 healthy controls. CHiCAGO was used to identify significant interactions (CHiCAGO score>5) for each cell type and disease condition (**Supplementary Table 6**) and Chicdiff was used to identify differential interactions between cell types, and between disease conditions for each cell type. A total of 81,624 and 74,853 significant interactions originating from 8,193 and 7,024 captured promoters were identified in CD4$^+$ T cells and CD14$^+$ monocytes, respectively. Through integration with published ChIP-seq data, we found that PIRs were enriched in H3K27ac and H3K4me3 histone marks from primary CD4$^+$ naive T cells and CD14$^+$ monocytes (**Supplementary Figure 2**), suggesting that promoters are more likely to interact with active regulatory regions such as enhancers.

Differential interactions and expression between SSc patients and healthy controls

We first attempted to identify specific interactions that could be present in SSc patients but not in healthy controls, or vice versa, and thus, identify specific genes interacting with enhancer regions and SSc GWAS loci that could be of interest in SSc pathology. We identified a total of 4,858 significant differential interactions (weighted adjusted p-value<0.05) between SSc patients and healthy controls in CD4$^+$ T cells, originating from 1,526 captured promoters, although the significance was modest (median weighted adjusted p-value=2.2×10^{-2}) as compared with differential interactions between cell types (median weighted adjusted p-value=2.16×10^{-10}). Moreover, we could not detect any significant differential interactions in CD14$^+$ monocytes, indicating weak differences in cells isolated from blood between patients and controls. None of the 23 SSc GWAS associated regions showed significant differences at the interaction level between patients and controls. Regarding the transcriptomic differences, we identified a total of 62 and 63 differentially expressed genes (FDR < 0.10) between patients and controls in CD4$^+$ T cells and CD14$^+$ monocytes, respectively (**Supplementary Tables 7** and **8**). In the case of CD4$^+$ T cells we observed significant enrichment in pathways related with immune response such as "positive regulation of immune system process" or "leukocyte activation" (**Supplementary Table 9**). However, we could not identify any functional enrichment regarding the 63 genes differentially expressed in CD14$^+$ monocytes. Taken together, these results indicate that only modest differences are present in cells isolated from peripheral blood from patients.

Identification of allele associated chromatin interactions

Recently there have been reports of allele associated chromatin interactions, these studies however were limited in size or had low resolution and based in cell lines (25,26). We wanted to test if allele associated interactions were present in our dataset of primary cells. To do this, for each individual, we assigned reads based on the haplotype of origin and quantified allelic imbalance in the read counts for all the CHiCAGO significant loops. We then aggregate the results for all the samples which were heterozygous for that SNP. After stringent quality control we identify 577 and 541 SNP-loop pairs in CD4$^+$ T cells and CD14$^+$ monocytes respectively (FDR<0.05) (**supplementary file 1 and 2**), representing 171 and 139 allele

associated loops in CD4[+] T cells and CD14[+] monocytes respectively. None of the SSc GWAS SNPs displayed allelic imbalance interactions at this statistical power, however we still identify allele associated interactions with important genes related to immunity. For example, in CD4[+] T cells we find allele associated interactions connecting the SNP rs661849 (located downstream of *IRF6*) and *TRAF3IP3* and *IRF6*. Interestingly this SNP is also an eQTL for these two genes, further validating our approach. In CD14[+] monocytes we identify allele associated interactions linking a group of SNPs located around the promoter of *GPX3* and the promoters of *GPX3* and *TNIP1*. Again, these SNPs were also identified as eQTLs for both genes, although these specific SNPs were not found to be associated with any disease in the GWAS catalog. Overall, we identify allele associated interactions between SNPs and 62 and 57 genes in CD4[+] T cells and CD14[+] monocytes respectively. Of these 38 and 31 respectively were also eQTL for those genes in the eQTLgen database (4 and 3 respectively in the DICE eQTL database).

Linking differential expression and differential interactions in CD4[+] T cells vs CD14[+] monocytes

Next, we decided to look at differences at the interaction and expression level between cell types and how these correlate with each other, without taking disease state into account. We identify 2,257 strongly differentially expressed genes (FDR<0.05, $|log_2FC|>2$) between CD4[+] T cells and CD14[+] monocytes, of which 919 and 1,338 genes were overexpressed in CD4[+] T cells and CD14[+] monocytes, respectively. Overrepresentation analyses showed that each group of genes is, as expected, significantly enriched in terms related with T cells and monocytes specific pathways, including gene ontology terms such as "T cell activation" and "T cell differentiation" in CD4[+] T cells, and "leukocyte activation" in CD14[+] monocytes (**Supplementary Tables 10** and **11**). Regarding the interactome, we identify 71,213 significant differential interactions (weighted adjusted p-value<0.05) originating from 8,223 captured promoters. We observed that differentially expressed genes are in fact significantly enriched in differentially interacting genes (fisher exact test p-value=3.54×10^{-37}, OR=1.77). Furthermore, from the total of 1,209 differentially expressed genes overlapping differentially interacting genes, we observed that genes overexpressed in a specific cell type significantly correlated with increased number of chromatin interactions in that cell type, and vice versa (Spearman's rank correlation p-value=1.04×10^{-197}, rho=0.73). Finally, we applied a more stringent cutoff in differentially interacting genes ($|log_2FC|>2$), leading to a total of 97 differentially expressed genes overlapping differential interactions. In this subset, only 2 of the 97 genes did not behave as expected; 23 and 72 genes were overexpressed and presented an increased number of interactions in CD4[+] T cells and CD14[+] monocytes, respectively (exact binomial test p-value=6.01×10^{-26}, probability of success=98%) (**Supplementary Figure 3**). Thus, our results show that chromatin conformation is highly cell type specific and linked to gene expression and demonstrate the importance of using the correct cell types to define promoter interactions and linking genes to GWAS loci.

SSc GWAS loci and CD4[+] / CD14[+] promoter interactions

Finally, we identify new potential target genes associated to SSc GWAS loci, as well as the potential implication of different cell types in those associations. We performed a multi-omic

approach overlapping 23 regions defined based on the most powerful SSc meta-GWAS performed to date (9) with enhancer regions and our pCHi-C data (see online **Supplementary Material and Methods** for more detail). In addition we have also integrated our findings with two large eQTL databases, eQTLgen, which is the largest blood eQTL meta-analysis (36), and DICE eQTL, which is the largest study that makes use of purified immune cell populations (35) (**supplementary file 3**). From the total of 1,505 SNPs genome-wide significant (p-value$<5x10^{-8}$) SNPs associated with SSc and those in high linkage disequilibrium ($r^2>0.8$) with them, 445 (29.6%) and 284 (18.9%) overlapped with enhancer regions from CD4$^+$ T cells and CD14$^+$ monocytes, respectively. As expected, the GWAS SNPs significantly enriched enhancer regions in both CD4$^+$ and CD14$^+$ (Garfield enrichment test OR=3.40, p-value $6.7x10^{-4}$ in CD4$^+$ T cells; OR=3.05, p-value $1.7x10^{-3}$ in CD14$^+$ monocytes). In addition, the differences in the number of SNPs overlapping CD4$^+$ and CD14$^+$ enhancer regions was significant (two proportion z-test p-value=0.001), showing a stronger enrichment with CD4$^+$ T cell enhancer regions as compared with that observed in CD14$^+$ monocytes. These GWAS SNPs within enhancer regions were overlapped with PIRs from pCHi-C, resulting in a total of 398 and 109 significant interactions in CD4$^+$ T cells and CD14$^+$ monocytes, respectively (**Supplementary Table 4**). The promoter ends of those interactions correspond to 46 genes, with a total of 40 and 27 interacting genes in CD4$^+$ T cells and CD14$^+$ monocytes, respectively (**Table 1**).

The physical interaction maps presented here identify 39 new potential candidate genes and confirm 7 genes which have been previously associated to SSc using genomic proximity. Differential expression and differential interaction data for each of the 46 genes and baited promoters are available in **Supplementary Tables 12** and **13**, respectively. Interestingly, some SSc confirmed genes such as *IRF8, STAT4*, or *CD247,* showed cell type specific interactions (**Figures 1-3**). The rs11117420 (*IRF8*) locus (**Figure 1**) provides a good example in which interactions between SNPs overlapping enhancer regions (represented by H3K27ac mark peaks) and the *IRF8* promoter are found exclusively in one cell type and is associated to differential gene expression between cells, in which CD14$^+$ monocytes showed a much higher expression of *IRF8* ($\log_2$FC=-4.47, FDR=$3.11x10^{-72}$). In the case of the rs3821236 (*STAT4*) locus (**Figure 2**), significant interactions with the *STAT4* promoter were identified exclusively in CD4$^+$ T cells, corresponding with a TAD specific for CD4$^+$ T cells that is not found in monocytes. In addition, *STAT4* showed a significantly higher expression in CD4$^+$ T cells as compared with CD14$^+$ monocytes ($\log_2$FC=7.05, FDR=$1x10^{-304}$). Interestingly, neither of these two loci showed eQTL signals to these genes in either database. rs11117420 was eQTL for a lncRNA gene (*RP11-542M13.3*) whilst rs3821236 only showed weak eQTL signals for *GLS* and *MFSD6*. Cell type specific interactions are also observed in the rs2056626 (*CD247*) GWAS locus (**Figure 3**), in which significant interactions between SNPs and the *CD247* promoter are identified only in CD4$^+$ T cells, with an increased expression of this gene in CD4$^+$ T cells as compared with CD14$^+$ monocytes ($\log_2$FC=7.49, FDR=$3.99x10^{-210}$). In this case we found that rs2056626 is also a strong eQTL for *CD247*.

On the other hand, we identified new potential candidate genes interacting with SSc GWAS associated SNPs, for example in the rs11217020 (*DDX6*) locus (**Figure 4**) we found

significant interactions between SNPs overlapping enhancer regions and not only *DDX6*, but also other potential candidate genes including *CXCR5*, *UPK2*, and *IFT46/ARCN1* promoters in CD4$^+$ T cells. In CD14$^+$ monocytes, only a significant interaction with *CXCR5* promoter was found. All of these interactions are intra-TAD, except for the one including *IFT46/ARCN1* promoters, and we observed a significantly higher gene expression of *CXCR5* (log$_2$FC=3.21, FDR=1.05x10^{-09}) and *DDX6* (log$_2$FC=1.14, FDR=2.38x10^{-83}) in CD4$^+$ T cells, while *ARCN1* showed a slight overexpression in CD14$^+$ monocytes (log$_2$FC=-0.21, FDR=3.69x10^{-03}). *ARCN1* and *CXCR5* are also eQTL hits for this SNP in blood (Supplementary Table), further supporting their role in SSc pathogenesis.

In order to identify what pathways could be driving disease in the two different cell types, we performed a functional enrichment analysis including the genes interacting with SSc GWAS loci for each cell type. In CD4$^+$ T cells, the set of 40 interacting genes observed showed enrichment in virus response and pancreatic carcinoma (**Supplementary Table 14**). In accordance with this, a higher incidence of cancer in SSc patients compared with the general population has been suggested in several studies (40). On the other hand, the set of 27 interacting genes observed in CD14$^+$ monocytes showed enrichment in tyrosine kinase activity (**Supplementary Table 15**), which plays an important role in fibrosis, and has been related with SSc pathogenesis, being tyrosine kinase inhibitors one of the most promising antifibrotic therapies for SSc and other fibrotic diseases (41).

Plots of the interactions for the rest of the SSc GWAS loci in CD4$^+$ T cells and CD14$^+$ monocytes can be found in **Supplementary Figures 4-22**. All eQTL hits are available in **Supplementary File 3**.

DISCUSSION

Our investigation integrates four dimensions in the study of SSc genetics; GWAS, chromosome conformation, gene expression, and cell-specificity. In this regard, our findings stress the importance of using the correct cell type in the functional interpretation of GWAS associations. We identified new target genes, and confirmed others, in SSc GWAS loci in two of the main cell types associated with the disease, CD4$^+$ T cells and CD14$^+$ monocytes. We also further validate the presence of interactions that are altered by common genomic variations and show how these are correlated with eQTLs.

One of the new candidate genes observed in pCHi-C data corresponds to CXC chemokine receptor type 5 (*CXCR5*) in the *DDX6* GWAS locus (**Figure 4**). *CXCR5* plays an important role in the differentiation of follicular helper T (Tfh) cells, and is highly expressed in CD4$^+$ and CD8$^+$ T cells (42). In addition, a recently published study observed that Tfh cells (CD4$^+$CXCR5$^+$PD-1$^+$) are increased in systemic sclerosis, and correlate with SSc severity (43). In line with the above, interactions with the promoter of this gene were identified specifically in CD4$^+$ T cells in our study, and the gene's expression was specific to this cell type. Furthermore, *CXCR5* has been associated through GWAS studies in other similar

immune-mediated diseases, such as rheumatoid arthritis or inflammatory bowel disease (44,45). Thus, *CXCR5* represents a good candidate gene contributing to SSc pathology, with a particular interest in CD4$^+$ T cells.

Another interesting example is found in the rs685985 (*RAB2A-CHD7*) locus, a recently discovered locus associated with SSc (9) (**Supplementary Figure 16**). Within this region, we observed significant interactions between SSc GWAS SNPs and the closest gene, *CHD7,* in CD4$^+$ T cells. *CHD7* is a chromatin remodeler that has been associated with lymphocyte (and other immune-related cells) counts in blood through GWAS (46). Regarding the rs589446 (*IL12A*) locus (**Supplementary Figure 9**), we identified long-range interactions between SSc GWAS SNPs and the promoter of *SMC4* in CD14$^+$ monocytes. *SMC* family genes play a central role in organizing and compacting chromosomes. In this line, a recent study showed *SMC4* promotes an inflammatory innate immune response, which is directly associated with monocyte activity, through enhancing NEMO transcription, an essential modulator of NF-Kb (47). Although *IL12A* has been traditionally set as the most probable candidate gene for this association, we did not observe any interactions between SSc GWAS SNPs and the promoter of this gene. Here, it is important to note the increased difficulty to identify significant short-range interactions (<50 kb) as background read count levels are dependent on the distance between fragments (28). This phenomenon represents a limitation in this kind of studies, as most of the GWAS SNPs are classically related with the closest gene, being these SNPs located within the gene itself in some cases. In this regard, newer high resolution Hi-C methods should help overcome the limitation of detecting very short range interactions (48).

Regarding previously confirmed genes associated with SSc, we described interactions between *IRF8* promoter and SSc GWAS SNPs that were only present in CD14$^+$ monocytes (**Figure 1**), corresponding with an upregulated expression of this gene in CD14$^+$ monocytes as compared with CD4$^+$ T cells. This transcription factor plays an important role in differentiation and regulation of monocytes and macrophages (49). Furthermore, variants in *IRF8* have been associated with monocyte counts across different populations (50), and a downregulation of *IRF8* in monocytes and macrophages of SSc patients that may affect the fibrotic phenotype of the disease was reported (51). A recent study demonstrated that the deletion of an enhancer region corresponding with our SSc GWAS locus in mice model decreased *Irf8* expression, resulting in an overproduction of inflammatory Ly6c$^+$ monocytes (52). Thus, our results confirm the association of *IRF8* with SSc through physical chromatin interactions particularly in CD14$^+$ monocytes. Although, given the evidence, this locus is very likely to affect *IRF8,* we did not find evidence of eQTL signals in the two databases we have explored. This is likely due to limitations of eQTL studies which require very large datasets to identify signals, which are very laborious to apply to all possible cell populations (in this case Monocytes). A recent study has also identified limitations in the design of eQTL studies when used to assign genes to GWAS loci (53). In other loci, *CD247* and *STAT4* have been described in many previous GWAS studies as main candidate genes associated with SSc (9,10). In our study interactions were exclusively found in CD4$^+$ T cells (**Figures 2-3**). These findings are in line with literature, as both genes play an important role particularly in T cell signaling and differentiation (54,55). Thus, our results highlight the importance of studying

GWAS signals with the specific cell types in which interactions are found, acting as a starting point for follow-up functional studies that can relate these signals with the disease.

As a proof of concept, we wanted to determine the potential for these genes to indicate novel treatment options for SSc. From the 46 genes that present PIRs overlapping significant SSc GWAS SNPs and enhancer regions, we identified a total of 21 drugs with interest in SSc targeting protein products in strong protein-protein interaction (PPI) with 13 of those genes (5 of them specific for CD4$^+$ T cells interactions) (**Table 2**). Fifteen of these drugs correspond to potential drug targets already in use, or at least in completed clinical phase III, in other similar immune-mediated diseases that could be repurposed for SSc treatment, such as metformin or dimethyl fumarate. Apart from new potential drug targets, tocilizumab and nintedanib were two of the drugs highlighted in our analysis, both of them approved by Food and Drug Administration (FDA) for its use in SSc-associated interstitial lung disease (56,57). We also identified 4 drugs which present advanced clinical trials developed in SSc (tofacitinib, bosentan, methylprednisolone and mycophenolic acid).

Our results reveal that 3D chromatin structure is largely preserved between SSc patients and healthy controls at least in CD4$^+$ T cells and CD14$^+$ monocytes derived from peripheral blood. So far, there is only one published study in which authors attempt to observe differences at the interaction level between patients and healthy controls in CD4$^+$ T cells from juvenile idiopathic arthritis patients (58). However, no differences at the interactome level were observed, which supports our hypothesis and underlines the difficulty to describe these subtle differences with current technology. Interestingly, it has been shown that subtle differences in chromatin interactions may be correlated with large functional effects on gene expression (25). More significant differences could be expected if cells were isolated from the site of active disease, and further studies involving these samples would be of great interest. On the other hand, we identify many significant allele-associated interactions and we are the first to show that this analysis is possible in primary cells isolated from patients. We show that many of the SNPs associated with these loops are also eQTLs for the genes they interact with. The overall number of loops presenting allelic imbalance is still very low compared to the loops tested (0.2%) but in line with previous studies (25,26). We think this is due to difficulties in assigning reads to a specific allele (only reads overlapping phased heterozygous sites can be tested) and the limited number of read pairs in long range interactions, consequently limiting statistical power.

Finally, we wanted to describe general differences between cell types at the interaction and expression level and how these are correlated. We observed that overexpressed genes in a specific cell type correlated with an increased number of interactions, and that those genes were enriched in specific pathways related with T cells and monocytes signaling, activation, and differentiation. These results demonstrate that interactions are directly related with the expression of important genes implicated in cell type specific pathways. In this regard, a recent study observed that disease-associated genes tend to be connected by cell-type-specific interactions (59). Thus, our data presented here will aid future studies to identify cell types enriched with interactions overlapping GWAS loci.

ACKNOWLEDGEMENTS

We greatly acknowledge the expert technical assistance of Sofía Vargas Roldán at the Institute of Parasitology and Biomedicine López-Neyra [IPBLN]–CSIC, as well as the assistance given by Information Technology Services and the use of the Computational Shared Facility at The University of Manchester, United Kingdom. This work is part of the Doctoral Thesis "Deciphering the genomic architecture of systemic sclerosis".

COMPETING INTEREST

Authors declare no competing interests.

DATA AVAILABILITY STATEMENT

The processed datasets generated from this study are available in the GEO repository under the accession number GSE212100.
Raw reads and genotypes can be provided upon reasonable request from the authors.

REFERENCES

1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.
2. Brown M, O'Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2019;195(3):310–21.
3. Stifano G, Christmann RB. Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence? Curr Rheumatol Reports 2015 181. 2015 Dec;18(1):1–6.
4. Pillai S. T and B lymphocytes in fibrosis and systemic sclerosis. Curr Opin Rheumatol. 2019 Nov;31(6):576–81.
5. Fuschiotti P. T cells and cytokines in systemic sclerosis. Curr Opin Rheumatol. 2018 Nov;30(6):594–9.
6. Bhandari R, Ball MS, Martyanov V, Popovich D, Schaafsma E, Han S, et al. Profibrotic Activation of Human Macrophages in Systemic Sclerosis. Arthritis Rheumatol. 2020 Jul;72(7):1160–9.
7. Soldano S, Trombetta AC, Contini P, Tomatis V, Ruaro B, Brizzolara R, et al. Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis. 2018 Dec;77(12):1842–5.
8. Moreno-Moral A, Bagnati M, Koturan S, Ko J-H, Fonseca C, Harmston N, et al. Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk. Ann Rheum Dis. 2018 Apr;77(4):596–601.
9. López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, et al. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nat Commun. 2019;10(1):1–14.
10. Radstake TRDJ, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010;42(5):426–9.
11. Bossini-Castillo L, López-Isac E, Martín J. Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways. J Autoimmun. 2015;64:53–65.
12. Orvain C, Assassi S, Avouac J, Allanore Y. Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr Opin Rheumatol. 2020 Nov;32(6):505–14.
13. Acosta-Herrera M, López-Isac E, Martín J. Towards a Better Classification and Novel Therapies Based on the Genetics of Systemic Sclerosis. Curr Rheumatol Rep. 2019;21(9):1–7.
14. Farh KK-H, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature [Internet]. 2015 Feb [cited 2018 Jun 12];518(7539):337–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25363779
15. Poppenberg KE, Tutino VM, Tarbell E, Jarvis JN. Broadening our understanding of genetic risk for scleroderma/systemic sclerosis by querying the chromatin architecture surrounding the risk haplotypes. BMC Med Genomics. 2021 Apr;14(1):1–12.
16. Rao SSP, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D Map of the Human Genome at Kilobase Resolution Reveals Principles of Chromatin Looping. Cell. 2014 Dec;159(7):1665–80.
17. Ding J, Frantzeskos A, Orozco G. Functional genomics in autoimmune diseases. Hum Mol Genet. 2020 Sep;29(R1):R59–65.
18. Dekker J, Rippe K, Dekker M, Kleckner N. Capturing chromosome conformation. Science (80-). 2002 Feb;295(5558):1306–11.
19. Lieberman-Aiden E, Van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A,

et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science (80-). 2009 Oct;326(5950):289–93.

20. Belton JM, McCord RP, Gibcus JH, Naumova N, Zhan Y, Dekker J. Hi–C: A comprehensive technique to capture the conformation of genomes. Methods. 2012 Nov;58(3):268–76.

21. Schoenfelder S, Javierre B-M, Furlan-Magaril M, Wingett SW, Fraser P. Promoter Capture Hi-C: High-resolution, Genome-wide Profiling of Promoter Interactions. JoVE (Journal Vis Exp. 2018 Jun;2018(136):e57320.

22. Javierre BM, Burren OS, Wilder SP, Kreuzhuber R, Hill SM, Sewitz S, et al. Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters. Cell [Internet]. 2016 Nov 17 [cited 2018 Jun 26];167(5):1369-1384.e19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27863249

23. Martin P, McGovern A, Orozco G, Duffus K, Yarwood A, Schoenfelder S, et al. Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. Nat Commun [Internet]. 2015;6:1–7. Available from: http://dx.doi.org/10.1038/ncomms10069

24. Martin P, Ding J, Duffus K, Gaddi VP, McGovern A, Ray-Jones H, et al. Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. Ann Rheum Dis. 2019 Aug;78(8):1127–34.

25. Greenwald WW, Li H, Benaglio P, Jakubosky D, Matsui H, Schmitt A, et al. Subtle changes in chromatin loop contact propensity are associated with differential gene regulation and expression. Nat Commun 2019 101. 2019 Mar;10(1):1–17.

26. Gorkin DU, Qiu Y, Hu M, Fletez-Brant K, Liu T, Schmitt AD, et al. Common DNA sequence variation influences 3-dimensional conformation of the human genome. Genome Biol [Internet]. 2019 Dec 28 [cited 2019 Nov 29];20(1):255. Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-019-1855-4

27. Wingett S, Ewels P, Furlan-Magaril M, Nagano T, Schoenfelder S, Fraser P, et al. HiCUP: pipeline for mapping and processing Hi-C data. F1000Research. 2015;4.

28. Cairns J, Freire-Pritchett P, Wingett SW, Várnai C, Dimond A, Plagnol V, et al. CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. Genome Biol [Internet]. 2016 Dec 15 [cited 2018 Apr 24];17(1):127. Available from: http://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-0992-2

29. Cairns J, Orchard WR, Malysheva V, Spivakov M. Chicdiff: a computational pipeline for detecting differential chromosomal interactions in Capture Hi-C data. Bioinformatics. 2019 Nov;35(22):4764–6.

30. Rubinacci S, Ribeiro DM, Hofmeister RJ, Delaneau O. Efficient phasing and imputation of low-coverage sequencing data using large reference panels. Nat Genet 2021 531 [Internet]. 2021 Jan 7 [cited 2022 Jul 27];53(1):120–6. Available from: https://www.nature.com/articles/s41588-020-00756-0

31. Bansal V. Integrating read-based and population-based phasing for dense and accurate haplotyping of individual genomes. Bioinformatics [Internet]. 2019 Jul 15 [cited 2022 Jul 27];35(14):i242–8. Available from: https://academic.oup.com/bioinformatics/article/35/14/i242/5529122

32. Krueger F, Andrews SR. SNPsplit: Allele-specific splitting of alignments between genomes with known SNP genotypes. F1000Research [Internet]. 2016 [cited 2022 Jul 27];5. Available from: https://pubmed.ncbi.nlm.nih.gov/27429743/

33. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics [Internet]. 2010 Mar 15 [cited 2018 Jul 7];26(6):841–2. Available from: https://academic.oup.com/bioinformatics/article-lookup/doi/10.1093/bioinformatics/btq033

34. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019 Jul;47(W1):W191–8.

35. Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-Gonzalo J, et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell [Internet]. 2018 Nov 29 [cited 2018 Dec 3];175(6):1701-1715.e16. Available from: https://www.sciencedirect.com/science/article/pii/S009286741831331X

36. Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Unraveling the polygenic architecture of complex traits using blood eQTL metaanalysis. bioRxiv [Internet]. 2018 Oct 19 [cited 2019 Jul 25];447367. Available from: https://www.biorxiv.org/content/10.1101/447367v1.supplementary-material

37. Boix CA, James BT, Park YP, Meuleman W, Kellis M. Regulatory genomic circuitry of human disease loci by integrative epigenomics. Nat 2021 5907845. 2021 Feb;590(7845):300–7.

38. Iotchkova V, Ritchie GRS, Geihs M, Morganella S, Min JL, Walter K, et al. GARFIELD classifies disease-relevant genomic features through integration of functional annotations with association signals. Nat Genet [Internet]. 2019 Feb 2 [cited 2022 Aug 8];51(2):343. Available from: /pmc/articles/PMC6908448/

39. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.

40. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento E V., La Vecchia C, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology. 2013 Jan;52(1):143–54.

41. Mendoza FA, Piera-Velazquez S, Jimenez SA. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Transl Res. 2021 May;231:139–58.

42. Moser B. CXCR5, the Defining Marker for Follicular B Helper T (TFH) Cells. Front Immunol. 2015;0(JUN):296.

43. Ricard L, Jachiet V, Malard F, Ye Y, Stocker N, Rivière S, et al. Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. Ann Rheum Dis. 2019 Apr;78(4):539–50.

44. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature [Internet]. 2014 Feb 25 [cited 2018 Jun 26];506(7488):376–81. Available from: http://www.nature.com/articles/nature12873

45. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nat 2012 4917422. 2012 Oct;491(7422):119–24.

46. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell. 2016 Nov;167(5):1415-1429.e19.

47. Wang Q, Wang C, Li N, Liu X, Ren W, Wang Q, et al. Condensin Smc4 promotes inflammatory innate immune response by epigenetically enhancing NEMO transcription. J Autoimmun. 2018 Aug;92:67–76.

48. Hua P, Badat M, Hanssen LLP, Hentges LD, Crump N, Downes DJ, et al. Defining genome architecture at base-pair resolution. Nat 2021 5957865. 2021

Jun;595(7865):125–9.

49. Salem S, Salem D, Gros P. Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases. Hum Genet 2020 1396. 2020 Mar;139(6):707–21.

50. Crosslin DR, McDavid A, Weston N, Zheng X, Hart E, de Andrade M, et al. Genetic variation associated with circulating monocyte count in the eMERGE Network. Hum Mol Genet. 2013 May;22(10):2119–27.

51. Ototake Y, Yamaguchi Y, Asami M, Komitsu N, Akita A, Watanabe T, et al. Downregulated IRF8 in Monocytes and Macrophages of Patients with Systemic Sclerosis May Aggravate the Fibrotic Phenotype. J Invest Dermatol. 2021 Aug;141(8):1954–63.

52. Murakami K, Sasaki H, Nishiyama A, Kurotaki D, Kawase W, Ban T, et al. A RUNX–CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes. Nat Immunol 2021 223. 2021 Feb;22(3):301–11.

53. Mostafavi H, Spence JP, Naqvi S, Pritchard JK. Limited overlap of eQTLs and GWAS hits due to systematic differences in discovery. bioRxiv [Internet]. 2022 May 8 [cited 2022 Jun 8];2022.05.07.491045. Available from: https://www.biorxiv.org/content/10.1101/2022.05.07.491045v1

54. Irving BA, Chan AC, Weiss A. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med. 1993 Apr;177(4):1093–103.

55. O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y. Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 2011 114. 2011 Mar;11(4):239–50.

56. Genetech Inc. Genentech's Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition. 2021.

57. FDA approves first treatment for patients with rare type of lung disease | FDA. 2019.

58. Tarbell E, Jiang K, Hennon TR, Holmes L, Williams S, Fu Y, et al. CD4+ T cells from children with active juvenile idiopathic arthritis show altered chromatin features associated with transcriptional abnormalities. Sci Reports 2021 111. 2021 Feb;11(1):1–14.

59. Mohammadi S, Davila-Velderrain J, Kellis M. Reconstruction of Cell-type-Specific Interactomes at Single-Cell Resolution. Cell Syst. 2019 Dec;9(6):559-568.e4.

FIGURE LEGENDS

Figure 1.
Promoter capture Hi-C (pCHi-C) interactions and gene expression in the rs11117420 (*IRF8*) GWAS locus. (**A**) Genomic coordinates (GRCh38) are shown at the top of the panel. The tracks include RefSeq genes (NCBI), systemic sclerosis (SSc) GWAS SNPs from López-Isac et al.(9) and those in high linkage disequilibrium (LD) (r^2>0.8), TADs (shown as bars), SNPs overlapping promoter interacting regions (PIRs) and enhancer regions, enhancer regions as defined by chromHMM, H3K27ac signal, and pCHi-C significant interactions (CHiCAGO score > 5) (shown as arcs) in CD4$^+$ T cells (blue) and CD14$^+$ monocytes (red). The highlighted region in red includes all the systemic sclerosis (SSc) SNPs LD block. (**B**) Gene expression level of *IRF8* from CD4$^+$ T cells and CD14$^+$ monocytes in counts per million (CPM). (**C**) Chicdiff bait profiles were generated for *IRF8* gene. The plot shows the raw read counts versus linear distance from the bait fragment as mirror images for CD4$^+$ T cells and CD14$^+$ monocytes. Other-end interacting fragments are pooled and color-coded by their adjusted weighted p-value. Significant differentially interacting regions detected by Chicdiff overlapping SSc GWAS SNPs and enhancer regions are depicted as red blocks.

Figure 2.
Promoter capture Hi-C (pCHi-C) interactions and gene expression in the rs11117420 (*STAT4*) GWAS locus. (**A**) Genomic coordinates (GRCh38) are shown at the top of the panel. The tracks include RefSeq genes (NCBI), systemic sclerosis (SSc) GWAS SNPs from López-Isac et al.(9) and those in high linkage disequilibrium (LD) (r^2>0.8), TADs (shown as bars), SNPs overlapping promoter interacting regions (PIRs) and enhancer regions, enhancer regions as defined by chromHMM, H3K27ac signal, and pCHi-C significant interactions (CHiCAGO score > 5) (shown as arcs) in CD4$^+$ T cells (blue) and CD14$^+$ monocytes (red). The highlighted region in red includes all the systemic sclerosis (SSc) SNPs LD block. (**B**) Gene expression level of *STAT4* and *NABP1* from CD4$^+$ T cells and CD14$^+$ monocytes in counts per million (CPM). (**C**) Chicdiff bait profiles were generated for *STAT4* and *NABP1* genes. Plots show the raw read counts versus linear distance from the bait fragment as mirror images for CD4$^+$ T cells and CD14$^+$ monocytes. Other-end interacting fragments are pooled and color-coded by their adjusted weighted p-value. Significant differentially interacting regions detected by Chicdiff overlapping SSc GWAS SNPs and enhancer regions are depicted as red blocks.

Figure 3.
Promoter capture Hi-C (pCHi-C) interactions and gene expression in the rs2056626 (*CD247*) GWAS locus. (**A**) Genomic coordinates (GRCh38) are shown at the top of the panel. The tracks include RefSeq genes (NCBI), systemic sclerosis (SSc) GWAS SNPs from López-Isac et al.(9) and those in high linkage disequilibrium (LD) (r^2>0.8), TADs (shown as bars), SNPs overlapping promoter interacting regions (PIRs) and enhancer regions, H3K27ac signal, enhancer regions as defined by chromHMM, and pCHi-C significant interactions (CHiCAGO

score > 5) (shown as arcs) in CD4$^+$ T cells (blue) and CD14$^+$ monocytes (red). The highlighted region in red includes all the systemic sclerosis (SSc) SNPs LD block. (**B**) Gene expression level of *CD247* and *CREG1* from CD4$^+$ T cells and CD14$^+$ monocytes in counts per million (CPM). (**C**) Chicdiff bait profiles were generated for *CD247* and *CREG1* genes. Plots show the raw read counts versus linear distance from the bait fragment as mirror images for CD4$^+$ T cells and CD14$^+$ monocytes. Other-end interacting fragments are pooled and color-coded by their adjusted weighted p-value. Significant differentially interacting regions detected by Chicdiff overlapping SSc GWAS SNPs and enhancer regions are depicted as red blocks.

Figure 4.
Promoter capture Hi-C (pCHi-C) interactions and gene expression in the rs11217020 (*DDX6*) GWAS locus. (**A**) Genomic coordinates (GRCh38) are shown at the top of the panel. The tracks include RefSeq genes (NCBI), systemic sclerosis (SSc) GWAS SNPs from López-Isac et al.(9) and those in high linkage disequilibrium (LD) (r^2>0.8), TADs (shown as bars), SNPs overlapping promoter interacting regions (PIRs) and enhancer regions, enhancer regions as defined by chromHMM, H3K27ac signal, and pCHi-C significant interactions (CHiCAGO score > 5) (shown as arcs) in CD4$^+$ T cells (blue) and CD14$^+$ monocytes (red). The highlighted region in red includes all the systemic sclerosis (SSc) SNPs LD block. (**B**) Gene expression level of *CXCR5*, *DDX6*, *ARCN1*, and *IFT46* from CD4$^+$ T cells and CD14$^+$ monocytes in counts per million (CPM). (**C**) Chicdiff bait profiles were generated for *CXCR5*, *DDX6*, *IFT46/ARCN1* (shared capture bait), and *UPK2* genes. Plots show the raw read counts versus linear distance from the bait fragment as mirror images for CD4$^+$ T cells and CD14$^+$ monocytes. Other-end interacting fragments are pooled and color-coded by their adjusted weighted p-value. Significant differentially interacting regions detected by Chicdiff overlapping SSc GWAS SNPs and enhancer regions are depicted as red blocks.

TABLES

Table 1. Promoter capture Hi-C target genes for the 23 systemic sclerosis associated regions in CD4[+] T cells and CD14[+] monocytes

Chr	Bp (start - end)[1]	GWAS Locus[2]	pCHi-C target genes[3]		CD4[+] vs CD14[+]	
			CD4[+] T cells	CD14[+] monocytes	Differential interactions	Differential expression
1	67326053 - 67448804	rs3790566 (IL12RB2)				
1	167445635 - 167465040	rs2056626 (CD247)	**CD247**, CREG1		**CD247**, CREG1	**CD247**, CREG1
1	173337507 - 173391947	rs1857066 (TNFSF4-LOC100506023 - PRDX6)				
2	190642047 - 190698201	rs16832798 (NAB1)	MFSD6, NEMP2	MFSD6, NEMP2, HIBCH;INPP1	MFSD6, NEMP2, HIBCH;INPP1	MFSD6, NEMP2, HIBCH, INPP1
2	191035723 - 191108308	rs3821236 (STAT4)	**STAT4**, NABP1		**STAT4**, NABP1	**STAT4**, NABP1
3	58084620 - 58482701	rs4076852 (FLNB -DNASE1L3-PXK)	RPP14, KCTD6	RPP14, KCTD6	RPP14, KCTD6	KCTD6
3	119384733 - 119546340	rs9884090 (POGLUT1-TIMMDC1-CD80- ARHGAP31)	TMEM39A;POGLUT1		TMEM39A;POGLUT1	TMEM39A, POGLUT1
3	160002484 - 160030580	rs589446 (IL12A)		SMC4;IFT80	SMC4;IFT80	SMC4, IFT80
4	960523 - 990021	rs11724804 (DGKQ)	GAK;TMEM175, FGFRL1	GAK;TMEM175, FGFRL1	FGFRL1	GAK, TMEM175 FGFRL1
4	102477892 - 102615256	rs230534 (NFKB1)	SLC39A8, **NFKB1**, UBE2D3;CISD2, SLC9B1, BDH2	SLC39A8, UBE2D3;CISD2, BDH2	SLC39A8, **NFKB1**, UBE2D3;CISD2, SLC9B1, BDH2	SLC39A8, UBE2D3, CISD2, BDH2
5	151064651 - 151080486	rs3792783 (TNIP1)				
6	106181815 - 106339294	rs633724 (ATG5)				
7	128933913 - 129095960	rs36073657 (IRF5-TNPO3)				
8	11474517 - 11544554	rs2736340 (FAM167A-BLK)				
8	60638547 - 60664239	rs685985 (RAB2A-CHD7)	ASPH, SDCBP, CHD7		ASPH, SDCBP	ASPH, SDCBP, CHD7
11	554659 - 619789	rs6598008 (CDHR5 -IRF7)				
11	2311894 - 2363262	rs2651804 (TSPAN32,CD81-AS1)	TSSC4		TSSC4	TSSC4
11	118704617 - 118875175	rs11217020 (DDX6)	CXCR5, UPK2, **DDX6**, IFT46;ARCN1	CXCR5	CXCR5, UPK2, **DDX6**	CXCR5, **DDX6**, ARCN1
15	74739180 - 75148328	rs1378942 (CSK)	**CSK**, CLK3, ULK3, SCAMP2, MPI, FAM219B, COX5A	**CSK**, CLK3, ULK3, SCAMP2, MPI, FAM219B, COX5A, C15orf39	**CSK**, ULK3, SCAMP2, MPI, FAM219B, COX5A, C15orf39	**CSK**, CLK3, ULK3, SCAMP2, MPI, FAM219B, COX5A, C15orf39
16	85932852 - 85979945	rs11117420 (IRF8)		**IRF8**	**IRF8**	**IRF8**
17	39747478 - 39933464	rs883770 (IKZF3-GSDMB)	**IKZF3**, ERBB2, PSMD3	ERBB2	**IKZF3**, ERBB2, PSMD3	**IKZF3**, ERBB2, PSMD3
17	75193533 - 75279345	rs1005714 (NUP85-GRB2)				
19	18068862 - 18093031	rs2305743 (IL12RB1)	PIK3R2, RAB3A	RAB3A	PIK3R2, RAB3A	

Genes classically associated with systemic sclerosis through proximity to GWAS loci are highlighted in bold.

[1]Bp in GRCh38 (hg 38) assembly

[2]Locus as defined by López-Isac et al.(9)

[3]Genes corresponding with promoter interacting regions overlapping enhancer regions and systemic sclerosis GWAS SNPs

Bp base pair, *Chr* chromosome, *GWAS* Genome-wide association studies, *N* number, *pCHi-C* promoter capture Hi-C, *SNP* single-nucleotide polymorphism.

Table 2. Summary of potential targets for drug repurposing in systemic sclerosis based on pCHi-C data

GWAS locus	pCHi-C interacting genes	Cell type with interactions	Genes in strong PPI	Targeted drug	Disease indication[$]
rs2056626	CREG1	CD4+ T cells	TUBB4B	Colchicine	Osteoarthritis, Advanced fibrosis
rs4076852	RPP14	CD4+ T cells, CD14+ monocytes	KEAP1	Dimethyl Fumarate	Psoriasis, Multiple sclerosis, Disseminated sclerosis
			AGTR1	Candesartan	Type 1 Diabetes
			HSPA8	Forigerimon	Systemic lupus erythematosus
rs230534	NFKB1	CD4+ T cells	IL12B	Ustekinumab	Psoriasis, Crohn´s disease, Ulcerative colitis
			IL1R1	Anakinra	Rheumatoid arthritis
			IL23A	Tildrakizumab	Psoriasis
			JAK2	Tofacitinib	**Systemic sclerosis**, Rheumatoid arthritis, Ulcerative colitis, Interstitial lung disease, Takayasu Arteritis
			NR3C1	Methylprednisolone*	Rheumatoid arthritis, Crohn´s disease, Psoriatic arthritis, Ulcerative colitis, Behcet´s syndrom
	UBE2D3	CD4+ T cells, CD14+ monocytes	KEAP1	Dimethyl Fumarate	Psoriasis, Multiple sclerosis, Disseminated sclerosis
rs685985	SDCBP	CD4+ T cells	IMPDH1	Mycophenolic acid*	Systemic lupus erythematosus, Immunosuppression
			TUBB4B	Colchicine	Osteoarthritis, Advanced fibrosis
	CHD7	CD4+ T cells	PPARG	Mesalamine	Crohn's disease, Ulcerative colitis
rs11217020	CXCR5	CD4+ T cells, CD14+ monocytes	S1PR3	Fingolimod	Multiple sclerosis, Disseminated sclerosis
rs1378942	CSK	CD4+ T cells, CD14+ monocytes	FLT4	Nintedanib	**Systemic sclerosis**, Idiopathic pulmonary fibrosis, Interstitial lung disease
	COX5A	CD4+ T cells, CD14+ monocytes	NDUFB10	Metformin	Type 1 Diabetes, Type 2 Diabetes
rs883770	IKZF3	CD4+ T cells	JAK1	Baricitinib	Rheumatoid arthritis
			JAK3	Upadacitinib	Rheumatoid arthritis
			IL2RA	Basiliximab	Type 1 Diabetes
	ERBB2	CD4+ T cells, CD14+ monocytes	IL6R	Tocilizumab	**Systemic sclerosis**, Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis
			JAK kinases	Tofacitinib	**Systemic sclerosis**, Rheumatoid arthritis, Ulcerative colitis, Interstitial lung disease, Takayasu Arteritis
rs2305743	PIK3R2	CD4+ T cells	ADRA1B	Epinephrine	Crohn's disease
			AGTR1	Candesartan	Type 1 Diabetes
			EDNRA	Bosentan	**Systemic sclerosis**, Idiopathic pulmonary fibrosis, Pulmonary arteria hypertension
			JAK1	Baricitinib	Rheumatoid arthritis
			JAK kinases	Tofacitinib	**Systemic sclerosis**, Rheumatoid arthritis, Ulcerative colitis, Interstitial lung disease, Takayasu Arteritis
			PDGFRB	Nintedanib	**Systemic sclerosis**, Idiopathic pulmonary fibrosis, Interstitial lung disease
	RAB3A	CD4+ T cells, CD14+ monocytes	HSPA8	Forigerimod	Systemic lupus erythematosus

[$]Only related immune-mediated diseases were included. All clinical trials at least in completed phase III.

*These drugs present phase III or lower clinical trials in systemic sclerosis.

GWAS genome-wide association studies, *pCHi-C* promoter capture Hi-C, *PPI* protein-protein interaction.

A

| Ruler | | | q24.1 | | |
| chr16 | 85800K | | 85900K | | 86000K |

RefSeq genes
EMC8
EMC8
COX4I1
IRF8

SSc GWAS SNPs

CD4+ T cell TADs

SNPs T cell overlap

CD4+ chromHMM
enhancer regions

CD4+ T cell
H3K27ac signal
42
0

CD4+ T cell pCHi-C

CD14+ monocyte TADs

SNPs monocyte overlap

CD14+ chromHMM
enhancer regions

CD14+ monocyte
H3K27ac signal
42
0

CD14+ monocyte pCHi-C

B

IRF8 expression

CPM

CD4+ T cells   CD14+ monocytes

C

IRF8

CD4+ T cells

N
90
60
30
0

85400000   85600000   85800000   86000000   86200000   86400000

p−values
> 0.05
0.005 − 0.05
0.0005 − 0.005
< 0.0005

85400000   85600000   85800000   86000000   86200000   86400000

N
0
30
60
90

CD14+ monocytes